Innovating Works

BIOMAP

Financiado
Biomarkers in Atopic Dermatitis and Psoriasis
Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manif... Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes. ver más
31/03/2025
CAU
22M€
Duración del proyecto: 73 meses Fecha Inicio: 2019-02-27
Fecha Fin: 2025-03-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-02-27
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 22M€
Líder del proyecto
CHRISTIANALBRECHTSUNIVERSITAET ZU KIEL No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5